CAMP- and Ca 2+/calmodulin-dependent protein kinases mediate inotropic, lusitropic and arrhythmogenic effects of urocortin 2 in mouse ventricular myocytes

British Journal of Pharmacology

Volumn 162, Issue 2, 2011, Pages 544-556

  Yang, Li Zhen ^a,b,c,d   Kocksk̈mper, Jens ^e,f   Khan, Shelina ^e   Suarez, Jorge ^b   Walther, Stefanie ^e   Doleschal, Bernhard ^e   Unterer, Gregor ^e   Khafaga, Mounir ^e   M̈cHler, Heinrich ^e   Heinzel, Frank R ^e   Dillmann, Wolfgang H ^b   Pieske, Burkert ^e   Spiess, Joachim ^a,c,g  

^a MAX PLANCK INSTITUTE OF EXPERIMENTAL MEDICINE   (Germany)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF HAWAII   (United States)

^d SHANGHAI JIAO TONG UNIVERSITY   (China)

^e MEDICAL UNIVERSITY OF GRAZ   (Austria)

^f PHILIPPS UNIVERSITY MARBURG   (Germany)

^g BURNHAM INSTITUTE   (United States)

Author keywords

Ca 2+ calmodulin dependent protein kinase II; mouse; protein kinase A; urocortin 2; ventricular myocyte

Indexed keywords

CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE; CYCLIC AMP; PHOSPHOLAMBAN; UROCORTIN II;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ARRHYTHMOGENESIS; ARTICLE; CALCIUM HOMEOSTASIS; CELL ISOLATION; CONTROLLED STUDY; DIASTOLE; FEMALE; GENE ACTIVATION; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HUMAN; HUMAN TISSUE; INOTROPISM; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION;

AGED; AGED, 80 AND OVER; ANIMALS; ARRHYTHMIAS, CARDIAC; CALCIUM; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASES; CARDIOTONIC AGENTS; CYCLIC AMP; CYCLIC AMP-DEPENDENT PROTEIN KINASES; FEMALE; HEART ATRIA; HEART VENTRICLES; HUMANS; MALE; MICE; MICE, INBRED C57BL; MIDDLE AGED; MUSCLE RELAXATION; MYOCARDIAL CONTRACTION; MYOCYTES, CARDIAC; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; UROCORTINS;

EID: 78650405397     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.01067.x     Document Type: Article

References (47)

1. Alexander SP, Mathie A, Peters JA, (2009). Guide to Receptors and Channels (GRAC). 4th edn. Br J Pharmacol 158 (Suppl. 1): S1-254.
2. Asaba K, Makino S, Nishiyama M, Hashimoto K, (2000). Regulation of type-2 corticotropin-releasing hormone receptor mRNA in rat heart by glucocorticoids and urocortin. J Cardiovasc Pharmacol 36: 493-497.
3. Bale TL, Hoshijima M, Gu Y, Dalton N, Anderson KR, Lee KF, et al. (2004). The cardiovascular physiologic actions of urocortin II: acute effects in murine heart failure. Proc Natl Acad Sci U S A 101: 3697-3702.
4. Brar BK, Jonassen AK, Stephanou A, Santilli G, Railson J, Knight RA, et al. (2000). Urocortin protects against ischemic and reperfusion injury via a MAPK-dependent pathway. J Biol Chem 275: 8508-8514.
5. Brar BK, Stephanou A, Knight R, Latchman DS, (2002). Activation of protein kinase B/Akt by urocortin is essential for its ability to protect cardiac cells against hypoxia/reoxygenation-induced cell death. J Mol Cell Cardiol 34: 483-492.
6. Burnett JC, Jr, (2005). Urocortin: advancing the neurohumoral hypothesis of heart failure. Circulation 112: 3544-3546.
7. Calderon-Sanchez E, Delgado C, Ruiz-Hurtado G, Dominguez-Rodriguez A, Cachofeiro V, Rodriguez-Moyano M, et al. (2009). Urocortin induces positive inotropic effect in rat heart. Cardiovasc Res 83: 717-725.
8. Chang CP, Pearse RV, 2nd, O'Connell S, Rosenfeld MG, (1993). Identification of a seven transmembrane helix receptor for corticotropin- releasing factor and sauvagine in mammalian brain. Neuron 11: 1187-1195.
9. Chen R, Lewis KA, Perrin MH, Vale WW, (1993). Expression cloning of a human corticotropin-releasing-factor receptor. Proc Natl Acad Sci U S A 90: 8967-8971.
10. Curran J, Hinton MJ, Rios E, Bers DM, Shannon TR, (2007). Beta-adrenergic enhancement of sarcoplasmic reticulum calcium leak in cardiac myocytes is mediated by calcium/calmodulin-dependent protein kinase. Circ Res 100: 391-398.
11. Davis ME, Pemberton CJ, Yandle TG, Lainchbury JG, Rademaker MT, Nicholls MG, et al. (2004). Urocortin-1 infusion in normal humans. J Clin Endocrinol Metab 89: 1402-1409.
12. Davis ME, Pemberton CJ, Yandle TG, Lainchbury JG, Rademaker MT, Nicholls MG, et al. (2005). Effect of urocortin 1 infusion in humans with stable congestive cardiac failure. Clin Sci (Lond) 109: 381-388.
13. Davis ME, Pemberton CJ, Yandle TG, Fisher SF, Lainchbury JG, Frampton CM, et al. (2007a). Urocortin 2 infusion in healthy humans: hemodynamic, neurohormonal, and renal responses. J Am Coll Cardiol 49: 461-471.
14. Davis ME, Pemberton CJ, Yandle TG, Fisher SF, Lainchbury JG, Frampton CM, et al. (2007b). Urocortin 2 infusion in human heart failure. Eur Heart J 28: 2589-2597.
15. Dunn AJ, Berridge CW, (1990). Physiological and behavioral responses to corticotropin-releasing factor administration: is CRF a mediator of anxiety or stress responses? Brain Res Brain Res Rev 15: 71-100.
16. Eckart K, Jahn O, Radulovic J, Tezval H, van Werven L, Spiess J, (2001). A single amino acid serves as an affinity switch between the receptor and the binding protein of corticotropin-releasing factor: implications for the design of agonists and antagonists. Proc Natl Acad Sci U S A 98: 11142-11147.
17. Eckart K, Jahn O, Radulovic J, Radulovic M, Blank T, Stiedl O, et al. (2002). Pharmacology and biology of corticotropin-releasing factor (CRF) receptors. Receptors Channels 8: 163-177.
18. Grossini E, Molinari C, Mary DA, Marino P, Vacca G, (2008). The effect of urocortin II administration on the coronary circulation and cardiac function in the anaesthetized pig is nitric-oxide-dependent. Eur J Pharmacol 578: 242-248.
19. Harmar AJ, (2001). Family-B G-protein-coupled receptors. Genome Biol 2: REVIEWS3013.
20. Ikeda K, Tojo K, Otsubo C, Udagawa T, Hosoya T, Tajima N, et al. (2005). Effects of urocortin II on neonatal rat cardiac myocytes and non-myocytes. Peptides 26: 2473-2481.
21. Kageyama K, Gaudriault GE, Bradbury MJ, Vale WW, (2000). Regulation of corticotropin-releasing factor receptor type 2 beta messenger ribonucleic acid in the rat cardiovascular system by urocortin, glucocorticoids, and cytokines. Endocrinology 141: 2285-2293.
22. Kockskamper J, Khafaga M, Grimm M, Elgner A, Walther S, Kockskamper A, et al. (2008). Angiotensin II and myosin light-chain phosphorylation contribute to the stretch-induced slow force response in human atrial myocardium. Cardiovasc Res 79: 642-651.
23. Lawrence KM, Kabir AM, Bellahcene M, Davidson S, Cao XB, McCormick J, et al. (2005). Cardioprotection mediated by urocortin is dependent on PKCepsilon activation. FASEB J 19: 831-833.
24. Mackay KB, Stiefel TH, Ling N, Foster AC, (2003). Effects of a selective agonist and antagonist of CRF2 receptors on cardiovascular function in the rat. Eur J Pharmacol 469: 111-115.
25. McMurray JJ, Pfeffer MA, (2005). Heart failure. Lancet 365: 1877-1889.
26. Nazarloo HP, Buttrick PM, Saadat H, Dunn AJ, (2006). The roles of corticotropin-releasing factor-related peptides and their receptors in the cardiovascular system. Curr Protein Pept Sci 7: 229-239.
27. Nishikimi T, Miyata A, Horio T, Yoshihara F, Nagaya N, Takishita S, et al. (2000). Urocortin, a member of the corticotropin-releasing factor family, in normal and diseased heart. Am J Physiol Heart Circ Physiol 279: H3031-H3039.
28. Parkes DG, Weisinger RS, May CN, (2001). Cardiovascular actions of CRH and urocortin: an update. Peptides 22: 821-827.
29. Perrin MH, Vale WW, (1999). Corticotropin releasing factor receptors and their ligand family. Ann N Y Acad Sci 885: 312-328.
30. Perrin MH, Donaldson CJ, Chen R, Lewis KA, Vale WW, (1993). Cloning and functional expression of a rat brain corticotropin releasing factor (CRF) receptor. Endocrinology 133: 3058-3061.
31. Rademaker MT, Charles CJ, Espiner EA, Fisher S, Frampton CM, Kirkpatrick CM, et al. (2002). Beneficial hemodynamic, endocrine, and renal effects of urocortin in experimental heart failure: comparison with normal sheep. J Am Coll Cardiol 40: 1495-1505.
32. Rademaker MT, Cameron VA, Charles CJ, Richards AM, (2005a). Integrated hemodynamic, hormonal, and renal actions of urocortin 2 in normal and paced sheep: beneficial effects in heart failure. Circulation 112: 3624-3632.
33. Rademaker MT, Charles CJ, Espiner EA, Frampton CM, Lainchbury JG, Richards AM, (2005b). Endogenous urocortins reduce vascular tone and renin-aldosterone/endothelin activity in experimental heart failure. Eur Heart J 26: 2046-2054.
34. Rademaker MT, Cameron VA, Charles CJ, Richards AM, (2006). Urocortin 3: haemodynamic, hormonal, and renal effects in experimental heart failure. Eur Heart J 27: 2088-2098.
35. Reyes TM, Lewis K, Perrin MH, Kunitake KS, Vaughan J, Arias CA, et al. (2001). Urocortin II: a member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. Proc Natl Acad Sci U S A 98: 2843-2848.
36. Ruhmann A, Bonk I, Lin CR, Rosenfeld MG, Spiess J, (1998). Structural requirements for peptidic antagonists of the corticotropin-releasing factor receptor (CRFR): development of CRFR2beta-selective antisauvagine-30. Proc Natl Acad Sci U S A 95: 15264-15269.
37. Spiess J, Rivier J, Rivier C, Vale W, (1981). Primary structure of corticotropin-releasing factor from ovine hypothalamus. Proc Natl Acad Sci U S A 78: 6517-6521.
38. Spiess J, Dautzenberg FM, Sydow S, Hauger RL, Ruhmann A, Blank T, et al. (1998). Molecular Properties of the CRF Receptor. Trends Endocrinol Metab 9: 140-145.
39. Stiedl O, Meyer M, Jahn O, Ogren SO, Spiess J, (2005). Corticotropin-releasing factor receptor 1 and central heart rate regulation in mice during expression of conditioned fear. J Pharmacol Exp Ther 312: 905-916.
40. Suarez J, Gloss B, Belke DD, Hu Y, Scott B, Dieterle T, et al. (2004). Doxycycline inducible expression of SERCA2a improves calcium handling and reverts cardiac dysfunction in pressure overload-induced cardiac hypertrophy. Am J Physiol Heart Circ Physiol 287: H2164-H2172.
41. Talukder MA, Norota I, Sakurai K, Endoh M, (2001). Inotropic response of rabbit ventricular myocytes to endothelin-1: difference from isolated papillary muscles. Am J Physiol Heart Circ Physiol 281: H596-H605.
42. Van Pett K, Viau V, Bittencourt JC, Chan RK, Li HY, Arias C, et al. (2000). Distribution of mRNAs encoding CRF receptors in brain and pituitary of rat and mouse. J Comp Neurol 428: 191-212.
43. Vita N, Laurent P, Lefort S, Chalon P, Lelias JM, Kaghad M, et al. (1993). Primary structure and functional expression of mouse pituitary and human brain corticotrophin releasing factor receptors. FEBS Lett 335: 1-5.
44. Waser B, Rehmann R, Rivier J, Vale W, Reubi JC, (2006). CRF receptors in the rodent and human cardiovascular systems: species differences. Peptides 27: 3029-3038.
45. Weisinger RS, Blair-West JR, Burns P, Denton DA, Purcell B, Vale W, et al. (2004). Cardiovascular effects of long-term central and peripheral administration of urocortin, corticotropin-releasing factor, and adrenocorticotropin in sheep. Endocrinology 145: 5598-5604.
46. Yang LZ, Kockskamper J, Heinzel FR, Hauber M, Walther S, Spiess J, et al. (2006). Urocortin II enhances contractility in rabbit ventricular myocytes via CRF(2) receptor-mediated stimulation of protein kinase A. Cardiovasc Res 69: 402-411.
47. Yang LZ, Tovote P, Rayner M, Kockskamper J, Pieske B, Spiess J, (2010). Corticotropin-releasing factor receptors and urocortins, links between the brain and the heart. Eur J Pharmacol 632: 1-6.